Save This Listing
Stumble It
Reporter Account  Create New Account  Login!
Search :
QUICK LINKS : Art & Entertainment Automotive Blogging & Social Media Business Computer Design Education Environment Events / Trade Shows  
shop now
forpressrelease.com
For PR Writing Services
forpressrelease.com
 
 
 
Press Release Details    
Add to Favorites  Mail to a Friend Print Page   Share This News Rate
Save This Listing     Stumble It          
71

RNCOS Releases a New Report - G-CSF Biosimilars Market Forecast to 2015

RNCOS has recently added a new Market Research Report titled, G-CSF Biosimilars Market Forecast to 2015 to its report gallery. For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great extent, from its current status. As per the estimations of our latest report, the global biosimilars market will expand at a CAGR of around 52% during 2010-2015. As the governments and private players around the world are stepping into the market, it is exhibiting bright prospects and immense opportunities to cash in on.

According to G-CSF Biosimilars Market Forecast to 2015, the overall market is presently dominated by first-generation biosimilars, and it is likely that their second-generation will grow phenomenally in the future. The Granulocyte colony-stimulating factor (G-CSF) biologics/biosimilars stimulate the production of neutrophils. In 2010, the G-CSF biosimilars had a 33% share in the global biosimilars market. It is expected that the patent expiries of Neupogen (filgrastim) in 2013 and Neulasta (pegfilgrastim) in 2015 will make the way for the entry of G-CSF biosimilars into the market. It is anticipated that the G-CSF biosimilars market will touch the US$ 350 Million-mark by 2015.

Our report analyzes the market for the global G-CSF biosimilars and looks into the recent activities in the segment. On studying the market trends and drivers, we found that rising business alliances are aiding the biosimilars development, and governments around the world are realizing the potential in biosimilars. The competitive landscape talks about the activities of companies like Sandoz, Hospira and Hexal, and their key G-CSF products. Overall, the extensive research presents an objective outlook of the global G-CSF biosimilars market to clients.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM393.htm

Some of our Related Reports are:

- Global RNAi Market Analysis (http://www.rncos.com/Report/IM329.htm)
- Global Gene Therapy Market Analysis (http://www.rncos.com/Report/IM282.htm)
- Cancer Monoclonal Antibodies Market to 2015 (http://www.rncos.com/Report/IM375.htm)
- Global Biosimilars Market Forecast to 2015(http://www.rncos.com/Report/IM379.htm)
- US Biotech Market Analysis (http://www.rncos.com/Report/IM0300.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.  
 
 

Contact Information

  • Name: Shushmul Maheshwari

    Company: RNCOS E-Services Pvt. Ltd.

    Telphone: 91-120-4224700 , -

    Address: B-129, Sector 6 Noida - 201301

    Email: press@rncos.com